Skip to content
  • Follow Us

CarboHyde

SUGAR IS LIFE

  • Home
  • About Us
  • Pipeline
  • Technology
  • Investors and Partnering
  • Career
  • CarboHyde News
  • CarboHyde’s Blog
  • Home
  • About Us
  • Pipeline
  • Technology
  • Investors and Partnering
  • Career
  • CarboHyde News
  • CarboHyde’s Blog

CarboHyde

SUGAR IS LIFE

  • Home
  • About Us
  • Pipeline
  • Technology
  • Investors and Partnering
  • Career
  • CarboHyde News
  • CarboHyde’s Blog

Tag: cell

Multivalent glycocyclopeptides: conjugation methods and biological applications

Nov 2, 2022Tamas Sohajdacarbohydratescell, chemistry, peptide, synthesis

Olivier Renaudet, David Goyard, Ángela Martín-Serrano Ortiz and Didier Boturynlick from Université Grenoble Alpes presents click chemistry to decorate synthetic multivalent scaffolds with glycans to mimic the cell surface glycocalyx and to develop applications in glycosciences.

Read the full article

Categories

  • carbohydrates
  • drug delivery
  • drug development
  • drug discovery
  • Egyéb kategória
  • news
  • Today's cyclodextrin

Archive

  • March 2023 (36)
  • February 2023 (34)
  • January 2023 (31)
  • December 2022 (23)
  • November 2022 (33)
  • October 2022 (38)
  • September 2022 (9)

Latest posts

  • Investigation of 2-Hydroxypropyl-β-Cyclodextrin Treatment in a Neuronal-Like Cell Model of Niemann–Pick Type C Using Quantitative Proteomics
  • A Guide to Your Desired Lipid-Asymmetric Vesicles
  • Grafting of Cyclodextrin to Theranostic Nanoparticles Improves Blood-Brain Barrier Model Crossing

Subscribe to our newsletter

alzheimers analytical chemistry anticancer atherosclerosis cancer research cancer treatment carbohyde cardiovascular chemistry cholesterol clinical trial covid19 cyclodextrin drug delivery formulation development gene therapy glycotime green chemistry infectious diseases monoclonal antibodies neurodegenerative diseases oncology research rare disease scientific advisory board synthesis

Developed by Shuttle Themes. Powered by WordPress.
  • Contact Us
  • LinkedIn
  • Twitter